GlassScriptPhysician profile
Kevin Ganesh
NPI 1225563026
$2,535.98
in general payments reported to CMS, 2019-2025
16 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $315 · 2023: $1,276 · 2024: $634 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $580.84 | 2022-2025 | Dificid, Recarbrio, Zerbaxa |
| Viiv Healthcare Company | $449.48 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $327.39 | 2022-2023 | Symtuza |
| Melinta Therapeutics, LLC | $257.54 | 2023-2025 | Kimyrsa, Rezzayo, Vabomere |
| Abbvie INC. | $228.33 | 2022-2025 | |
| Shionogi INC | $194.03 | 2023-2025 | Fetroja |
| Smith+Nephew, INC. | $116.93 | 2023-2025 | Collagenase Santyl, Regranex |
| Janssen Products, LP | $99.00 | 2022 | |
| Lilly USA, LLC | $69.59 | 2022-2024 | Emgality, Jardiance |
| Amgen INC. | $48.16 | 2022-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.57 | 2023 | Jardiance |
| Gilead Sciences, INC. | $36.18 | 2023 | |
| Insmed, INC. | $29.24 | 2024 | Arikayce |
| Aimmune Therapeutics, INC. | $22.77 | 2024 | |
| Pfizer INC. | $22.72 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ganesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.